Search results
The American Macular Degeneration Foundation Showc | Newswise
Newswise· 6 days ago“Our goal is to advance the development of treatments, tools and usable information that improve the lives of those affected by AMD and, just as important, a sense of hope ...
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and...
Yucaipa News Mirror· 6 days agoAge-related macular degeneration (AMD) is a leading cause of severe vision loss for people aged 50 years and older in developed countries worldwide, with ...
Age-Related Macular Degeneration: Putting a Hole in Our World
WebMD· 4 days agoWhen we’re young, we take our macula for granted. At the center of our retina – the deepest layer of the eye that’s chock-full of photoreceptors and that confers color to our world – the macula ...
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results By Investing.com
Investing.com· 4 days agoIn a recent earnings call, Lineage Cell Therapeutics (NYSE:LCTX), a biotechnology company...
Ranibizumab is Safe for Treating Retinopathy of Prematurity
UB Reporter· 2 days agoFor several decades, laser therapy has been the primary treatment method for ROP. Laser treatment involves burning the infant’s peripheral retina to stop ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 20 hours agoTinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related ...
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
GuruFocus.com via Yahoo Finance· 4 days agoIts flagship product, ADVM-022 (Ixo-vec), aims to revolutionize care for patients with wet age-related macular degeneration (AMD) by reducing the frequency ...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...
Lodi News-Sentinel· 22 hours agoGLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month ...
Disease latency bias and the protective effect of metformin against age-related macular degeneration...
Nature· 4 days agoThere arises a spurious association between the older medication and absence of the condition causing symptoms. Metformin is an old medication, but it remains the first-line treatment ...
Red flag sign in your eye of silent killer that causes 75,000 UK deaths a year
Daily Express· 3 days agoHigh blood pressure - or hypertension - is a medical condition that is thought to affect around a...